×
About 7,498 results

ALLMedicine™ Aspartate Aminotransferase Center

Research & Reviews  2,752 results

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment.
https://doi.org/10.1007/s00280-021-04329-8 10.1093/annonc/mdy181 10.1016/S1470-2045(19)30029-4 10.1016/S1470-2045(13)70240-7 10.1007/s10637-017-0451-2 10.1634/theoncologist.2019-0565 10.1016/S1470-2045(19)30145-7 10.1093/annonc/mdx372.035 10.1200/jco.2004.22.90140.6051 10.1002/cpdd.336 10.1016/j.ejca.2008.10.026 10.1056/NEJMoa1611310 10.1056/NEJMoa1910962 10.1016/j.ygyno.2018.12.009
Cancer Chemotherapy and Pharmacology; Akce M, El-Khoueiry A et. al.

Jul 30th, 2021 - The purpose of this study is to characterize niraparib pharmacokinetics (PK) and safety in patients with normal hepatic function (NHF) versus moderate hepatic impairment (MHI). Patients with advanced solid tumors were stratified by NHF or MHI (Nat...

The application of cytokeratin-18 as a biomarker for drug-induced liver injury.
https://doi.org/10.1007/s00204-021-03121-0 10.4254/wjh.v9.i10.491 10.2353/ajpath.2009.080976 10.1155/2016/9737920 10.1016/j.therap.2018.02.004 10.1093/toxsci/kfs243 10.1093/toxsci/kfy282 10.1055/s-2003-42640 10.18632/oncotarget.12325 10.1016/j.ajpath.2018.12.006 10.1002/jps.3030470706 10.1002/(SICI)1096-9896(199807)185:3 10.1083/jcb.138.6.1379 10.1111/liv.13441 10.1002/hep.29802 10.1016/bs.apha.2019.03.001 10.1016/s0955-0674(01)00301-5 10.1124/jpet.105.088898 10.1016/j.prp.2020.152901 10.1152/ajpgi.00575.2005 10.1111/j.1600-0773.1964.tb01784.x 10.1007/s00210-019-01618-1 10.1016/S0960-9822(98)70438-5 10.5858/arpa.2014-0214-RA 10.1016/j.nmd.2013.09.004 10.1002/pds.1207 10.1111/j.1478-3231.2006.01380.x 10.1208/aapsj080106 10.1111/j.1572-0241.1999.01321.x 10.14218/jcth.2014.00014 10.1016/j.taap.2009.04.018 10.1111/j.1572-0241.2000.01707.x 10.1158/0008-5472.can-03-2455 10.1074/jbc.272.52.33197 10.1152/ajpgi.1999.277.6.G1108 10.1002/hep.20948 10.1002/(sici)1096-9896(199904)187:5 10.3181/00379727-102-25357 10.3748/wjg.v24.i37.4230 10.1177/0192623317707271 10.1533/9781908818270.1.25 10.1097/00001574-199905000-00005 10.1016/j.bbadis.2018.08.037 10.1172/JCI59755 10.1016/j.taap.2012.08.015 10.1016/0006-2952(91)90249-5 10.1080/01926230590881808 10.1016/0041-008X(88)90040-3 10.1158/1078-0432.Ccr-08-0111 10.1016/0092-8674(82)90400-7 10.1016/0140-6736(93)91818-7 10.3233/cbm-2009-0597 10.1016/j.tibs.2006.05.008 10.7326/0003-4819-137-12-200212170-00007 10.1007/s10620-015-3916-1 10.1001/archinte.1965.03860140008003 10.1245/s10434-012-2438-8 10.1053/j.gastro.2014.03.050 10.1152/ajpgi.00364.2014 10.1016/j.yexcr.2004.02.019 10.1038/209036a0 10.1016/j.bcp.2019.113664 10.1126/science.1260419 10.1016/j.cgh.2019.11.050 10.1002/hep.22633 10.1080/713611034 10.1038/clpt.2012.96 10.1016/j.taap.2015.09.022 10.1021/acs.jproteome.9b00047 10.1016/j.clinbiochem.2006.12.010 10.1186/s40779-015-0039-0 10.1111/j.1365-2036.2009.04148.x
Archives of Toxicology; Korver S, Bowen J et. al.

Jul 30th, 2021 - Drug-induced liver injury (DILI) is a frequent and dangerous adverse effect faced during preclinical and clinical drug therapy. DILI is a leading cause of candidate drug attrition, withdrawal and in clinic, is the primary cause of acute liver fail...

GWAS of serum ALT and AST reveals an association of SLC30A10 Thr95Ile with hypermangane...
https://doi.org/10.1038/s41467-021-24563-1 10.1016/j.jhep.2018.09.014 10.1016/j.cgh.2011.03.020 10.1038/nrd4051 10.1016/j.drudis.2008.11.009 10.1093/toxsci/kfy265 10.1007/s10519-013-9593-y 10.1056/NEJM200004273421707 10.1371/journal.pone.0004435 10.1371/journal.pgen.0020132 10.1016/j.jhep.2008.12.025 10.1080/00365510902814646 10.1093/clinchem/47.1.81 10.1515/CCLM.2010.031 10.1038/ng.970 10.1002/oby.22527 10.5808/GI.2013.11.3.149 10.1038/s41598-018-37832-9 10.1038/s41588-018-0047-6 10.1038/ng.531 10.1038/ng.939 10.1038/s41598-017-10812-1 10.1186/s12916-019-1364-z 10.1016/j.cell.2019.10.004 10.1093/bioinformatics/bty1032 10.1038/ng.257 10.1056/NEJMoa1712191 10.1186/1471-2164-5-32 10.1016/j.ajhg.2012.01.018 10.1177/0883073810393962 10.1136/adc.83.5.439 10.1002/ana.24131 10.1016/j.ajhg.2012.01.017 10.1289/ehp.10421 10.1007/s10545-008-0813-1 10.1016/S0002-9343(88)80066-4 10.1126/science.aaf6814 10.1371/journal.pgen.1008629 10.1371/journal.pgen.1001324 10.1038/s41598-018-24219-z 10.1093/hmg/ddv190 10.1007/s00424-016-1913-7 10.1016/j.ajhg.2018.11.008 10.1016/j.cell.2016.10.042 10.1093/nar/gkz828 10.1371/journal.pone.0200785 10.1038/s41588-018-0302-x 10.1038/ng.3949 10.1016/j.jhep.2020.03.032 10.1016/j.bbalip.2016.04.013 10.1126/science.aaz1776 10.1038/s41586-019-1631-3 10.1038/s41467-018-06318-7 10.1038/s41586-019-1373-2 10.1523/JNEUROSCI.2329-14.2014 10.1016/j.ajhg.2008.09.012 10.1002/cpt.629 10.1111/acer.13949 10.1158/1078-0432.CCR-15-2044 10.1038/ng0896-399 10.1038/ng.2901 10.1038/ng.2926 10.1038/ncomms5309 10.1038/ng2101 10.1038/s41467-018-07460-y 10.1086/421527 10.1212/WNL.0b013e31824c4682 10.2337/db12-1692 10.1038/ncomms7069 10.1002/art.34390 10.1074/jbc.M116.726935 10.1016/j.ajhg.2015.11.003 10.1038/ncomms11601 10.1074/jbc.RA119.008762 10.1172/JCI129710 10.1172/JCI133120 10.1111/liv.13284 10.1016/j.jhep.2015.10.009 10.2486/indhealth.42.111 10.1007/s12011-008-8119-6 10.1093/jn/116.1.135 10.1038/nature14248 10.1002/nbm.931 10.1007/s40572-015-0056-x 10.1038/nature13595 10.1002/ajmg.b.32545 10.1038/s41598-020-70108-9 10.1016/S0140-6736(95)92164-8 10.1001/archneur.60.4.521 10.1007/s11910-019-0942-y 10.1182/blood.V94.6.1864 10.1002/hep.24351 10.1016/S0140-6736(13)61903-0 10.5487/TR.2010.26.2.083 10.1093/nar/gkt1113 10.1002/mds.25031 10.1126/science.aal4043 10.1093/bioinformatics/btr599 10.1038/s41588-018-0184-y 10.1056/NEJMoa1508419 10.1111/biom.13214 10.1038/s41586-018-0579-z 10.21105/joss.00731 10.1093/bioinformatics/btq340 10.1186/s13742-015-0047-8 10.1093/bioinformatics/btq033 10.1186/s13059-016-0974-4 10.1038/s41586-020-2308-7 10.1038/nature24277 10.1093/nar/gky1120 10.1038/s41586-020-2853-0 10.1093/bioinformatics/btp324 10.1038/s41588-018-0144-6 10.1093/nar/gkv1340 10.1111/tra.12371 10.1093/nar/gky1016 10.1038/nprot.2015.123 10.1038/nmeth0410-248
Nature Communications; Ward LD, Tu HC et. al.

Jul 29th, 2021 - Understanding mechanisms of hepatocellular damage may lead to new treatments for liver disease, and genome-wide association studies (GWAS) of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) serum activities have proven useful f...

Clinical Significance of the Fibrosis-4 Index in Patients with Acute Heart Failure Requ...
https://doi.org/10.1536/ihj.20-793
International Heart Journal; Shirakabe A, Okazaki H et. al.

Jul 20th, 2021 - The Fibrosis-4 (FIB4) index could indicate the liver fibrosis in patients with chronic hepatic diseases. It was calculated using the following formula: (age × aspartate aminotransferase [U/L]) / (platelet count [103/μL] × √alanine aminotransferase...

see more →

Guidelines  1 results

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
https://doi.org/10.1038/ajg.2016.517
The American Journal of Gastroenterology; Kwo PY, Cohen SM et. al.

Dec 21st, 2016 - Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests sh...

see more →

Drugs  38 results see all →

Clinicaltrials.gov  64 results

MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
https://clinicaltrials.gov/ct2/show/NCT02575339

Apr 17th, 2020 - OUTLINE: This is a multi-center trial. The phase 1 dose escalation trial will evaluate MLN0128 in a standard 3+3 successive cohort design to identify the highest planned dose level. Phase II trial subjects will be 1:1 randomized to receive either ...

Liver Test Study of Using JKB-122 in AIH Patients
https://clinicaltrials.gov/ct2/show/NCT02556372

Jan 29th, 2020 - This is a Phase 2, pilot study in which JKB-122 is given once daily for 24 weeks to subjects with AIH who have liver enzymes that are 1.25 to 10 times the upper limit of normal (ULN) and who have had a failed response to, incomplete response to, i...

Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT03323346

Jan 18th, 2020 - Inclusion criteria: Patients with stage IV breast cancer with metastases demonstrated by appropriate imaging techniques Histologically or cytologically confirmed tumor Age of 18 years or more Eastern Cooperative Oncology Group (ECOG) performance s...

Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal...
https://clinicaltrials.gov/ct2/show/NCT03666832

Dec 30th, 2019 - Inclusion Subjects who are males or females ≥ 19 years of age Subjects who have the following history of first-line gemcitabine and nab-paclitaxel among patients with cytologically or histologically proven metastatic pancreatic ductal adenocarcino...

Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1
https://clinicaltrials.gov/ct2/show/NCT03212521

Sep 4th, 2019 - A study to evaluate the efficacy and safety of glecaprevir(GLE)/pibrentasvir(PIB) in treatment-naïve participants with chronic hepatitis C virus (HCV) genotypes 1-6 infection and with an aspartate aminotransferase to platelet ratio index (APRI) of...

see more →

News  144 results

Gene Therapy for Spinal Muscular Atrophy Safe, Improves Motor Function
https://www.staging.medscape.com/viewarticle/936296

Aug 26th, 2020 - NEW YORK (Reuters Health) - For children with spinal muscular atrophy (SMA), gene therapy with onasemnogene abeparvovec-xioi (Zolgensma) is safe and provides improvements in motor function, report clinicians from Ohio. SMA is a rare genetic diseas...

Selpercatinib 'Poised to Alter the Landscape' of RET+ve Cancers
https://www.staging.medscape.com/viewarticle/936368

Aug 26th, 2020 - Clinical data for the first-ever RET inhibitor, selpercatinib (Retevmo), show efficacy in two groups of patients with cancer ― those with RET fusion–positive non–small cell lung cancer (NSCLC), and those with RET-mutant medullary thyroid cancer (M...

Why Biliary Atresia Demands Our Respect
https://www.medscape.com/viewarticle/935660

Aug 19th, 2020 - As I listened to our fellow present the case of a 5-month-old infant referred for evaluation of persistent jaundice, painful memories of several similar cases flashed by, causing me to ask, "Is this another late diagnosis of biliary atresia?" This...

Hepatotoxicity Tied to Remdesivir COVID-19 Treatment
https://www.medscape.com/viewarticle/933529

Jul 8th, 2020 - NEW YORK (Reuters Health) - Although remdesivir treatment may shorten time to recovery in patients with COVID-19, it may also induce liver injury, possibly in combination with P-glycoprotein inhibitors, according to a case report by Dutch investig...

Fast Five Quiz: Heart Failure Presentation and Diagnosis
https://reference.medscape.com/viewarticle/912857_5

Apr 23rd, 2020 - BNP is the strongest predictor of heart failure vs other causes of dyspnea. High LV filling pressures stimulate the release of BNP, which exerts diuretic, natriuretic, and antihypertensive effects by inhibiting the renin-angiotensin-aldosterone sy...

see more →